These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 18651118)

  • 1. [Secondary prevention after myocardial infarction].
    Pflumm JE; Pomykaj T; Heintzen MP
    Internist (Berl); 2008 Sep; 49(9):1052-60. PubMed ID: 18651118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Secondary prevention of cardiovascular diseases].
    Schneider CA; Erdmann E
    Internist (Berl); 2004 Jun; 45 Suppl 1():S23-30. PubMed ID: 15148584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Secondary Prevention Medication on the Prognosis in Patients With Myocardial Infarction With Nonobstructive Coronary Artery Disease.
    Abdu FA; Liu L; Mohammed AQ; Xu B; Yin G; Xu S; Xu Y; Che W
    J Cardiovasc Pharmacol; 2020 Dec; 76(6):678-683. PubMed ID: 33284169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal secondary prevention medication use in acute myocardial infarction patients with nonobstructive coronary artery disease is modified by management strategy: insights from the TRIUMPH Registry.
    Pitts R; Daugherty SL; Tang F; Jones P; Ho PM; Tsai TT; Spertus J; Maddox TM
    Clin Cardiol; 2017 Jun; 40(6):347-355. PubMed ID: 28387960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A specialist in clinical hypertension critiques ALLHAT.
    Meltzer JI
    Am J Hypertens; 2003 May; 16(5 Pt 1):416-20. PubMed ID: 12745205
    [No Abstract]   [Full Text] [Related]  

  • 6. Medical Therapy for Secondary Prevention and Long-Term Outcome in Patients With Myocardial Infarction With Nonobstructive Coronary Artery Disease.
    Lindahl B; Baron T; Erlinge D; Hadziosmanovic N; Nordenskjöld A; Gard A; Jernberg T
    Circulation; 2017 Apr; 135(16):1481-1489. PubMed ID: 28179398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of secondary medical prevention after primary vascular reconstruction: studies on usage and effectiveness.
    Høgh AL
    Dan Med J; 2012 Sep; 59(9):B4514. PubMed ID: 22951205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current therapies for secondary prevention after myocardial infarction.
    Cannon CE; Smith SC
    Curr Opin Cardiol; 1999 Mar; 14(2):155-60. PubMed ID: 10191975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP).
    Fonarow GC; Gawlinski A; Moughrabi S; Tillisch JH
    Am J Cardiol; 2001 Apr; 87(7):819-22. PubMed ID: 11274933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of antiplatelet drugs in the prevention of cardiovascular events.
    Tendera M; Wojakowski W
    Thromb Res; 2003 Jun; 110(5-6):355-9. PubMed ID: 14592562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacologic plaque passivation for the reduction of recurrent cardiac events in acute coronary syndromes.
    Monroe VS; Kerensky RA; Rivera E; Smith KM; Pepine CJ
    J Am Coll Cardiol; 2003 Feb; 41(4 Suppl S):23S-30S. PubMed ID: 12644337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholesterol end points predict outcome in patients with coronary disease: quality improvement metrics from the enhancing secondary prevention in coronary artery disease (ESP-CAD) trial.
    McAlister FA; Majumdar SR; Lin M; Bakal J; Fradette M; Anderson T
    Can J Cardiol; 2014 Dec; 30(12):1627-32. PubMed ID: 25307535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving lipid control following myocardial infarction.
    Ankam J; Feldman DI; Blaha MJ; Martin SS
    Curr Opin Cardiol; 2014 Sep; 29(5):454-66. PubMed ID: 25046003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medical management of stable coronary artery disease.
    Pflieger M; Winslow BT; Mills K; Dauber IM
    Am Fam Physician; 2011 Apr; 83(7):819-26. PubMed ID: 21524048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients.
    Naderi SH; Bestwick JP; Wald DS
    Am J Med; 2012 Sep; 125(9):882-7.e1. PubMed ID: 22748400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Factors influencing secondary prevention of atherothrombotic disease in the private outpatient cardiology setting: results of the Prisma survey].
    Cambou JP; Ferrieres J; Grenier O; Boka G; Cantet C; Leizorovicz A
    Ann Cardiol Angeiol (Paris); 2003 Feb; 52(1):20-9. PubMed ID: 12710291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atherogenic dyslipidemia in the cardiometabolic syndrome.
    Govindarajan G; Chowdhury N; Flaker G
    J Cardiometab Syndr; 2006; 1(2):153-5. PubMed ID: 17679818
    [No Abstract]   [Full Text] [Related]  

  • 18. Heart attacks: gone with the century?
    Brown MS; Goldstein JL
    Science; 1996 May; 272(5262):629. PubMed ID: 8614809
    [No Abstract]   [Full Text] [Related]  

  • 19. Fixed dose combination therapy and CVD protection: "a need of the hour".
    Chopra HK
    Indian Heart J; 2009; 61(4):316-21. PubMed ID: 20635732
    [No Abstract]   [Full Text] [Related]  

  • 20. Prevalence of use of antiplatelet drugs, beta blockers, statins, and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in older patients with coronary artery disease in an academic nursing home.
    Joseph J; Koka M; Aronow WS
    J Am Med Dir Assoc; 2008 Feb; 9(2):124-7. PubMed ID: 18261706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.